Amgen Inc.

Glaxo Group Limited

Leo-pharma A/s

Chronos Therapeutics Limited

Glaxosmithkline Istrazivacki Center Zagret D.o.o.

Alfonso Pozzan

Romano Di Fabio

Ning Chen

Qingyian Liu

Fabrizio Micheli

Jakob Felding

Aaron C Siegmund

Vu Van Ma

Karl Richard Gibson

Gorjana Lazarevski

Morten Dahl Sørensen

Luca Tarsi

Barbara Bertani

Susanna Cremonesi

Teresa Semeraro

Sergio Lociuro

Antun Hutinec

Stjepan Mutak

Zorica Marusic-Istuk

Iain Lingard

Francesca Cardullo

Maria Pia Catalani

Andrea Berdik

Suleman Alihodzic

Marko Derek

Federica Tonelli

Haakon Bladh

Luca Raveglia

Timothy Jon Luker

Riccardo Zanaletti

Giulia Lattanzi

Sabrina Tassini

Morten Dahl SØRENSEN

The present disclosure provides compounds useful for the inhibition of Delta-5 Desaturase (“D5D”). The compounds have a general Formula 1: wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a metabolic or cardiovascular disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use

There is provided a compound of formula (I), wherein Lto L', Rto R, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.

Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists

The present invention relates to a compound according to formula (A) wherein n is 1 or 2; R1 and R2 are independently hydrogen, Calkyl, Chaloalkyl, Calkoxy, CD3 or halogen; R3 is hydrogen, C(&#x2550;O)OR7 or Calkyl optionally substituted with hydroxy or NR8R9; R4 is hydrogen or oxo; R5 and R6 are independently hydrogen, hydroxy, NR8R9, C(&#x2550;O)R7, C(&#x2550;O)OR7, C(&#x2550;O)NR8R9, Calkyl, wherein said Calkyl is optionally substituted with hydroxy, NR8R9 or a 5- or 6-membered heterocyclic ring, wherein said 5- or 6-membered heterocyclic ring is optionally substituted with Calkyl or C(&#x2550;O)R7; or R5 and R6, together with the carbon atom to which they are attached, form &#x2550;CHor a 5- or 6-membered heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted with Calkyl; R7 is hydrogen or Calkyl; R8 and R9 are independently hydrogen or Calkyl, or R8 and R9, together with the nitrogen atom to which they are attached, form a 5- or 6-membered heterocyclic ring, or a pharmaceutically acceptable salt or solvate thereof. The invention relates further to intermediates for the preparation of said compounds, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating or ameliorating pruritic dermal diseases or conditions with said compounds, and to the use of said compounds in the manufacture of medicaments. 

Substituted pyrrolo[1,2-a]piperazines and pyrrolo[1,2-a][1,4]diazepines as neurokinin 1 receptor antagonists

The invention relates to novel semi-synthetic macrolides of formula (I) having antibacterial activity. More particularly this invention relates to derivatives of 8a-aza-8a-homoerythromycin A, to processes for their preparation, to compositions containing them and to their use in medicine 

Macrolides

Growing community of inventors

Verona, Italy

Alfonso Pozzan